Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease, erosive oesophagitis, Zollinger‑Ellison syndrome and to prevent NSAID‑induced gastric ulcers in adult patients.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nolpaza (pantoprazole) is indicated for conditions that involve excess gastric acid production.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the esophageal lining. - Erosive oesophagitis: reduces acid exposure to allow ulcerated esophageal tissue to heal. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid caused by gastrin‑producing tumors. - Prevention of NSAID‑induced gastric ulcers: protects the stomach lining in patients taking non‑steroidal anti‑inflammatory drugs.

Pantoprazole is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools that may be transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Liver enzyme elevation: abnormal blood test results indicating hepatic stress. - Bone fracture risk: especially with long‑term use in high‑risk populations. - Acute interstitial nephritis: kidney inflammation presenting with fever and urinary changes.

Before initiating therapy with Nolpaza, consider the following safety measures.

- Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic status: use with caution in patients with liver disease. - Monitor long‑term use: prolonged therapy may increase risk of fractures and vitamin B12 deficiency. - Pregnancy: category B, generally considered safe but only if clearly needed. - Breastfeeding: limited data; weigh benefits against potential infant exposure. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption; avoid concurrent use. - Atazanavir: markedly decreased antiviral levels; contraindicated. - Clopidogrel: diminished antiplatelet effect; consider alternative therapy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: modest rise in serum levels; check renal function and drug levels. - Methotrexate (high dose): reduced clearance; monitor for toxicity. - Calcium carbonate or iron supplements: may decrease pantoprazole absorption; separate dosing by at least 2 hours.